查詢結果分析
來源資料
頁籤選單縮合
題 名 | 口服麩醯胺以預防化學治療引起的周邊神經病變=Oral Glutamine for Prevention of Chemotherapy-Induced Peripheral Neuropathy |
---|---|
作 者 | 徐昀耀; 陳怡靜; 蔡圭豐; | 書刊名 | 腫瘤護理雜誌 |
卷 期 | 9:1 2009.06[民98.06] |
頁 次 | 頁13-22 |
專 輯 | 化學治療引起神經病變之相關議題 |
分類號 | 415.831、415.831 |
關鍵詞 | 麩醯胺; 化學治療; 周邊神經病變; Glutamine; Chemotherapy; Peripheral neuropathy; |
語 文 | 中文(Chinese) |
中文摘要 | 化學治療所引起的周邊神經病變(chemotherapy-induced peripheral neuropathy, CIPN)是使用taxanes (paclitaxel, docetaxel)、platinum (cisplatin, carboplatin, oxaliplatin)及vinca alkaloids (vincristine, vinblastine, vinorelbine)類化學治療藥物引起的副作用,它們可能造成化療病患的不適,也影響其生活品質。一旦發生此副作用,即使該病患對此種化療藥物仍具療效反應,還是會被迫調降化療劑量,以致療程拖延甚或治療中斷。然而,對於CIPN,至今卻仍無一標準治療方法。麩醯胺(Glutamine)為一非必需(nonessential)胺基酸,由於其具有向上調控神經生長因子(upregulation of nerve growth factor)的特性,或許能提供神經保護作用的益處,進而幫助減少CIPN的發生。在過去文獻中顯示,口服麩醯胺可以有效減低因使用高劑量paclitaxel或是oxaliplatin造成的周邊神經病變,包括:減少麻木感、不悅異常感(dysesthesias),運動困難及較少的振動感覺減損(vibratory sensation loss)等,但對神經傳導並無影響。由於這些研究受限於樣本數較少,且在對照組病患未給予安慰劑治療;因此,若欲以口服麩醯胺來預防paclitaxel或oxaliplatin引起的周邊神經病變,仍有待大型、設計完整且於對照組投與安慰劑的臨床試驗結果,以確立其臨床療效,進而作為學術及臨床照護之參考依據。 |
英文摘要 | Chemotherapy-induced peripheral neuropathy (CIPN) is a significant adverse effect during chemotherapy. These chemotherapy regimens, such as taxanes (paclitaxel, docetaxel), platinum (cisplatin, carboplatin, oxaliplatin) and vinca alkaloids (vincristine, vinblastine, vinorelbine), had many neurotoxic effects. This CIPN lets the patients uncomfortable and decreased their quality of life. We more concerned to CIPN because it often leads to reduce chemotherapeutic dosage, delay treatment, and discontinue whole chemotherapy course, even though the patient had good response to these drugs. However, there is no standard protocol of caring patient, prevention and treatment to CIPN. Glutamine is a nonessential amino acid in biochemistry that is thought to have a neuro-protective role. It might be upregulated of nerve growth factor and help to reduce CIPN. Many studies evaluated the role of oral glutamine for prevention and treatment of CIPN recently. These studies revealed that oral glutamine had effects in reducing peripheral neuropathy associated with high-dose paclitaxel and oxaliplatin, as evidenced by reduction in numbness, dysesthesias, and motor weakness, as well as a smaller loss of vibratory sensation, however, does not appear to have any effect on the deterioration of nerve conduction in the subject. Nevertheless, data are limited by small sample sizes in these studies and the lack of placebo-controlled, randomized clinical trials. More sample sizes, well-designed, placebocontrolled trials assessing both safety and efficacy of oral glutamine are warranted before this agent can be definitively recommended for the prevention of CIPN in patients treated with high dose paclitaxel or oxaliplatin. If the therapeutic effect of glutamine in CIPN is improved, it will be valuable reference in academic and clinical care. |
本系統中英文摘要資訊取自各篇刊載內容。